Novo's full results from a late-stage trial show its Wegovy injection helped children ages 6 to under 12 with obesity lower their body mass index. Wegovy reduced BMI by an estimated 19.7 percentage points on average compared with a placebo at 68 weeks, assuming patients stayed on treatment. When the analysis included every child, including those who discontinued, the estimated average reduction was 16.2 percentage points more than placebo. Those are meaningful numbers, and they deserve attention from parents, clinicians and regulators.

The case for taking this seriously is strong. Childhood obesity, as the report describes it, can bring cardiovascular, metabolic and psychosocial consequences, and few treatment options exist for children under 12. Nearly half of the 167 children in the study already had at least one obesity-related complication, such as high blood pressure, high cholesterol or sleep apnea. Novo also reported that more than 40% of treated children were no longer classified as having obesity after 68 weeks, assuming they stayed on treatment, and that safety and tolerability were consistent with trials in adults. Against a projected rise to 228 million affected children and teens worldwide by 2040, a treatment option for the youngest patients is not a small matter.

Still, the enthusiasm should be measured. Every child in the study also received lifestyle modifications, including a reduced-calorie diet and increased physical activity, so these results cannot be cleanly separated from the effect of that program. The headline figures also rely on an assumption that patients stayed on treatment, and the more conservative all-patient estimate is smaller. A two-year study is useful, but it does not show whether treating obesity earlier changes a child's long-term trajectory, as Dr. Andrea Traina acknowledged when she called that an evidence gap.

My view is that regulators and pediatric specialists should review the full data carefully before any approval for children under 12, with particular attention to the all-patient analysis and to what happens after treatment ends. Novo should commit to longer follow-up into adolescence and adulthood, since the central question is durability, not just early weight change. Families facing this disease deserve a real option, but they also deserve a clear account of what remains unknown. Promising is the right word for these results. Proven is not yet earned.